NCT06669078Not yet recruitingPhase 2
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer
A Prospective, Open, Randomized Controlled, Multicenter, Exploratory Clinical Study of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 1 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of the prospective, open, randomized controlled, multicenter, exploratory clinical study is to evaluate efficacy and safety of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 27 Oct 2024
- Start date
- 30 Oct 2024
- Primary completion date
- 15 Oct 2027
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Diseases
- Pancreatic cancer
- NCT number
- NCT06669078
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 120
- From 30 Oct 2024 to the primary completion date, 15 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior anti-tumor therapy of any kind;
- Patients with autoimmune disease or immune deficiency who are treated with immuno-suppressive drugs;
Other illness
- Patients with bleeding tendency;
Other
- Known to be symptomatic central nervous system metastasis and/or cancerous meningitis.
- Pregnant or lactating women.
Who the study is looking for
- Histologically or cytologically confi rmed pancreatic cancer;
- ECOG performance no more than 1;
- Radiographically assessed as locally advanced pancreatic cancer according ;
- No previous anti-tumor therapy;
- Able and willing to provide a written informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.